移植免疫抑制剤の世界市場：予測（2025年～2030年）

世界の移植免疫抑制剤の市場規模は、CAGR4.08%で、2025年の67億2,700万米ドルから2030年には82億1,400万米ドルに成長すると予測されます。

移植免疫抑制剤市場は、移植技術の進歩、慢性疾患の増加、世界人口の高齢化などを背景に力強い成長を遂げています。これらの薬剤は、免疫反応を抑制することで臓器拒絶反応を防ぎ、臓器移植の長期的な成功を保証するために不可欠です。臓器移植とそれを支援する医薬品の需要が増加し続けていることから、市場はさらなる拡大が見込まれています。

主な成長促進要因

臓器移植手術件数の増加が市場促進の主要因です。低侵襲手術や腹腔鏡下手術などの手術手技の進歩により、移植成功率が向上し、これらの手術がより安全で利用しやすくなっています。生体ドナー移植やペア臓器交換プログラムなどの革新的なアプローチは、利用可能な臓器のプールを拡大し、移植件数をさらに増加させています。米国臓器移植ネットワーク（UNOS）のような政府、ヘルスケア組織、非営利団体による支援イニシアティブは、臓器割り当てシステムを強化し、移植インフラを強化し、臓器提供に関する意識を高め、移植件数の増加とそれに伴う免疫抑制剤需要の拡大に貢献しています。

目次

第1章 エグゼクティブサマリー

第2章 市場スナップショット

• 市場概要
• 市場の定義
• 調査範囲
• 市場セグメンテーション

第3章 ビジネス情勢

• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析
• 業界バリューチェーン分析
• ポリシーと規制
• 戦略的提言

第4章 技術の展望

第5章 移植免疫抑制剤市場：タイプ別

• イントロダクション
• 導入薬
• 維持薬
• 拒絶反応抑制薬

第6章 移植免疫抑制剤市場：移植タイプ別

• イントロダクション
• 組織移植
• 臓器移植
• 腎臓移植
• 肝臓移植
• 心臓移植
• 肺移植
• 膵臓移植
• その他

第7章 移植免疫抑制剤市場：薬剤クラス別

• イントロダクション
• カルシニューリン阻害剤
• mTOR阻害剤
• 抗増殖剤
• モノクローナル抗体
• ポリクローナル抗体
• コルチコステロイド
• その他

第8章 移植免疫抑制剤市場：投与経路別

• イントロダクション
• 経口
• 静脈内
• その他

第9章 移植免疫抑制剤市場：エンドユーザー別

• イントロダクション
• 病院
• 移植センター
• 専門クリニック
• その他

第10章 移植免疫抑制剤市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • スペイン
  • その他
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • インドネシア
  • タイ
  • その他

第11章 競合環境と分析

• 主要企業と戦略分析
• 市場シェア分析
• 合併・買収・協定・協業
• 競合ダッシュボード

第12章 企業プロファイル

• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• Sanofi Genzyme
• Novartis Pharmaceuticals Corporation
• Mylan N.V.
• Hoffmann-La Roche Ltd
• Accord Healthcare
• Viatris Inc.

第13章 付録

• 通貨
• 前提条件
• 基準年と予測年のタイムライン
• 利害関係者にとっての主なメリット
• 調査手法
• 略語

The Transplant Immunosuppressive Drugs Market is expected to grow from USD 6.727 billion in 2025 to USD 8.214 billion in 2030, at a CAGR of 4.08%.

The transplant immunosuppressive drugs market is experiencing robust growth, driven by advancements in transplantation techniques, rising chronic disease prevalence, and an aging global population. These drugs are essential for preventing organ rejection by suppressing the immune response, ensuring the long-term success of organ transplants. The market is poised for further expansion as demand for organ transplantation and supportive pharmaceuticals continues to rise.

Key Growth Drivers

The increasing volume of organ transplant surgeries is a primary market driver. Advancements in surgical techniques, including minimally invasive procedures and laparoscopic methods, have improved transplant success rates, making these procedures safer and more accessible. Innovative approaches, such as living donor transplants and paired organ exchange programs, have expanded the pool of available organs, further increasing transplant numbers. Supportive initiatives from governments, healthcare organizations, and non-profits, such as the United Network for Organ Sharing (UNOS) in the United States, have strengthened organ allocation systems, enhanced transplantation infrastructure, and raised awareness about organ donation, contributing to higher transplant volumes and subsequent demand for immunosuppressive drugs.

Market Segmentation

The market is segmented by transplant type into tissue and organ transplantation, with organ transplantation commanding a significant share. Kidney, liver, heart, and lung transplants are the most prevalent, alongside other procedures like allograft transplants (e.g., face, hands, and abdominal wall). The high frequency of these surgeries directly drives the need for immunosuppressive drugs to ensure graft survival and patient recovery.

Regional Dynamics

Geographically, the market spans North America, South America, Europe, the Middle East and Africa, and Asia Pacific. North America is a leading region, propelled by advancements in tissue engineering, increased healthcare spending, and a high volume of organ transplant surgeries. The region's well-developed healthcare infrastructure and coordinated organ allocation systems further support market growth.

Pharmaceutical Innovations

Recent advancements in pharmaceutical research have introduced new and improved immunosuppressive drugs designed to enhance efficacy, reduce side effects, and improve patient outcomes. These innovations address challenges such as long-term immunosuppression risks, including toxicity and infection, thereby supporting market expansion by meeting the needs of transplant recipients more effectively.

Demographic Influences

The aging population significantly contributes to market growth, as older individuals are more susceptible to organ failure and chronic conditions like cardiovascular disease, diabetes, and cancer. These conditions often necessitate organ transplants, increasing the demand for immunosuppressive drugs. As the global geriatric population grows, this trend is expected to continue, further fueling market expansion.

The transplant immunosuppressive drugs market is set for sustained growth, driven by rising transplant volumes, technological advancements in surgical and pharmaceutical fields, and demographic shifts toward an older population. North America remains a key growth hub, supported by robust healthcare systems and organ allocation initiatives. Ongoing innovations in drug development and transplantation techniques will continue to meet the increasing global demand for effective post-transplant care, ensuring the market's upward trajectory.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2020 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation:

By Type

• Induction Drugs
• Maintenance Drugs
• Anti-Rejection Drugs

By Transplant Type

• Tissue Transplantation
• Organ Transplantation
• Kidney Transplantation
• Liver Transplantation
• Heart Transplantation
• Lung Transplantation
• Pancreas Transplantation
• Others

By Drug Class

• Calcineurin Inhibitors
• mTOR Inhibitors
• Antiproliferative Agents
• Monoclonal Antibodies
• Polyclonal Antibodies
• Corticosteroids
• Others

By Route of Administration

• Oral
• Intravenous
• Others

By End-User

• Hospitals
• Transplant Centers
• Specialty Clinics
• Others

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY TYPE

• 5.1. Introduction
• 5.2. Induction Drugs
• 5.3. Maintenance Drugs
• 5.4. Anti-Rejection Drugs

6. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY TRANSPLANT TYPE

• 6.1. Introduction
• 6.2. Tissue Transplantation
• 6.3. Organ Transplantation
• 6.4. Kidney Transplatation
• 6.5. Liver Transplantation
• 6.6. Heart Transplantation
• 6.7. Lung Transplantation
• 6.8. Pancreas Transplantation
• 6.9. Others

7. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY DRUG CLASS

• 7.1. Introduction
• 7.2. Calcineurin Inhibitors
• 7.3. mTOR Inhibitors
• 7.4. Antiproliferative Agents
• 7.5. Monoclonal Antibodies
• 7.6. Polyclonal Antibodies
• 7.7. Corticosteroids
• 7.8. Others

8. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY ROUTE OF ADMINISTRATION

• 8.1. Introduction
• 8.2. Oral
• 8.3. Intravenous
• 8.4. Others

9. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY END-USER

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Transplant Centers
• 9.4. Specialty Clinics
• 9.5. Others

10. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY GEOGRAPHY

• 10.1. Introduction
• 10.2. North America
  • 10.2.1. USA
  • 10.2.2. Canada
  • 10.2.3. Mexico
• 10.3. South America
  • 10.3.1. Brazil
  • 10.3.2. Argentina
  • 10.3.3. Others
• 10.4. Europe
  • 10.4.1. Germany
  • 10.4.2. France
  • 10.4.3. United Kingdom
  • 10.4.4. Spain
  • 10.4.5. Others
• 10.5. Middle East and Africa
  • 10.5.1. Saudi Arabia
  • 10.5.2. UAE
  • 10.5.3. Others
• 10.6. Asia Pacific
  • 10.6.1. China
  • 10.6.2. India
  • 10.6.3. Japan
  • 10.6.4. South Korea
  • 10.6.5. Indonesia
  • 10.6.6. Thailand
  • 10.6.7. Others

11. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 11.1. Major Players and Strategy Analysis
• 11.2. Market Share Analysis
• 11.3. Mergers, Acquisitions, Agreements, and Collaborations
• 11.4. Competitive Dashboard

12. COMPANY PROFILES

• 12.1. Astellas Pharma Inc.
• 12.2. Bristol-Myers Squibb Company
• 12.3. Sanofi Genzyme
• 12.4. Novartis Pharmaceuticals Corporation
• 12.5. Mylan N.V.
• 12.6. Hoffmann-La Roche Ltd
• 12.7. Accord Healthcare
• 12.8. Viatris Inc.

13. APPENDIX

• 13.1. Currency
• 13.2. Assumptions
• 13.3. Base and Forecast Years Timeline
• 13.4. Key Benefits for the Stakeholders
• 13.5. Research Methodology
• 13.6. Abbreviations